First-Line Treatment and Survival in Women Aged ≥ 70 Years with De Novo Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Multicenter Cohort Study by the Turkish Oncology Group


Creative Commons License

Eniseler E. B., Erdoğan A. P., Şahbazlar M., Şahin G., Çakar B., Demirkıran Ö., ...Daha Fazla

JOURNAL OF CLINICAL MEDICINE, cilt.15, sa.22, ss.1-22, 2026 (SCI-Expanded, Scopus)

Özet

Background: Real-world evidence regarding first-line treatment selection and clinical outcomes in women aged 70 years and older with de novo hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer remains limited. This study evaluated treatment patterns, survival outcomes, and treatment-related adverse events in this population. Methods: This multicenter retrospective study included 181 women aged ≥ 70 years with de novo HR+/HER2− metastatic breast cancer treated at 14 oncology centers in Türkiye between January 2016 and January 2026. Patients receiving first-line cyclin-dependent kinase 4/6 inhibitors plus aromatase inhibitors (CDK4/6i + AI; n = 136) were compared with those receiving other first-line regimens (n = 45). Treatment selection was evaluated using logistic regression, while progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier estimates and Cox regression. Results: CDK4/6i + AI was administered to 75.1% of patients. ECOG performance status ≥ 2 was independently associated with lower odds of receiving combination treatment (adjusted odds ratio [aOR], 0.24; p = 0.003), whereas higher baseline left ventricular ejection fraction was associated with greater treatment receipt (aOR per 5-percentage-point increase, 1.62; p = 0.002). Median PFS was significantly longer with CDK4/6i + AI than with other treatments (43.6 vs. 12.9 months; p < 0.001), and this association persisted after adjustment, including HER2 status (adjusted hazard ratio [aHR], 0.48; 95% CI, 0.27–0.86; p = 0.013). No significant OS difference was observed (48.9 vs. 46.1 months; p = 0.205). Neutropenia was more frequent with CDK4/6i + AI (70.6% vs. 31.1%; p < 0.001). Recorded renal adverse events were also more frequent (12.5% vs. 0%; p = 0.008), although these could not be reliably distinguished from isolated creatinine elevations. Conclusions: First-line CDK4/6i + AI therapy was associated with longer PFS, without a significant OS difference, in older women with de novo HR+/HER2− metastatic breast cancer. Treatment selection was associated with functional status and cardiac function, supporting individualized therapeutic decisions beyond chronological age.